| |
• Nemera’s pen injector platform verified with SCHOTT Pharma’s cartriQ® 3 ml ready-to-use glass cartr.e system;
• Compatibility testing confirms seamless and reliable integration of delivery device and primary packaging, ensuring optimal device performance and patient safety;
• Partnership supports growing demand for patient-centric injectable therapies in homecare settings.
To support the industry shift from hospital to homecare including a more convenient drug administration for patients, SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, and Nemera, a world-leading provider of drug delivery device solutions and combination product services, have strengthened their partnership to provide pharmaceutical companies with a reliable, fully verified platform for injectable therapies.
“As healthcare increasingly moves closer to patients, pharmaceutical companies need to combine drug containment and delivery from the outset”, says Christian Mias, CEO of SCHOTT Pharma. “Together with Nemera, we are helping them address this growing demand through a proven and compatible platform solution.”
“Our collaboration with SCHOTT Pharma reflects our commitment to providing integrated drug delivery solutions that help simplify development and accelerate time to market”, says Marc Hämel, CEO of Nemera. “At Nemera, we believe that strong partnerships are essential to helping pharmaceutical companies bring combination products to patients more efficiently.”
Strategic partnership to address evolving patient needs
As therapeutic combination products require seamless integration between the delivery device and the pharmaceutical primary packaging system, SCHOTT Pharma’s and Nemera’s partnership supports optimal product performance as well as patient safety and comfort.
With more than two decades of experience in high-volume manufacturing of pen injectors and autoinjectors, Nemera offers a comprehensive portfolio of proprietary pen injector platforms developed with full intellectual property ownership. These platforms are designed to accommodate a broad range of prescription therapies, address diverse patient needs, and are manufactured in Nemera’s state-of-the-art facilities using advanced automation technologies.
At the same time, SCHOTT Pharma’s cartriQ® ready-to-use (RTU) glass cartridge system, manufactured from FIOLAX® Type I borosilicate glass with controlled hydrolytic resistance, is specifically designed to meet the demanding requirements of pen injectors, autoinjectors, and pump systems. Its robust mechanical resistance, excellent cosmetic quality, and tight dimensional tolerances support precise processing and reliable device functionality. Quality is ensured through 100% camera-controlled inspection, while geometric tolerances exceed ISO 13926-1 standards and can be further tightened for highly demanding applications.
Precisely controlled inner and outer diameters of the cartridge contribute to improved manufacturing robustness, enhanced visual inspection performance, and greater dose accuracy. In particular, tightly controlled inner diameters help minimize overfill losses in multidose applications, while advanced defect detection capabilities support cartridge integrity, sterility, and overall product quality.
Verified compatibility reduces risk and accelerates development
A comprehensive study was conducted by Nemera’s laboratory in Poland on the mechanical and chemical performance of 3 ml cartriQ® RTU cartridges. The evaluation focused on critical performance parameters, including break-loose and gliding forces (BLGF), as well as inorganic and organic leachable profiles, following accelerated aging conditions. Testing was performed in accordance with recognized industry standards, including ISO 21881 and ICH Q3D guidelines.
To further assess compatibility, additional assessments covered dimensional accuracy, filling volume performance, air-bubble evaluation, and density measurements. SCHOTT Pharma’s glass cartridge system met all predefined acceptance criteria, demonstrating excellent compatibility with Nemera’s pen injector platforms and providing high confidence in the combined solution.
The successful completion of these evaluations confirms the full technical compatibility between the respective products from SCHOTT Pharma and Nemera. Pharmaceutical companies can therefore benefit from a commercially available, verified integrated solution that accelerates development timelines while mitigating technical risks associated with combination products.
Together, SCHOTT Pharma and Nemera (nemera.net) are committed to supporting pharmaceutical partners with high-quality, reliable solutions for injectable drug delivery ultimately helping patients access treatments that are safe, effective, and easy to use.Bringing treatment closer to patients: Patient-centric drug delivery solutions support the growing trend toward convenient and comfortable administration in home healthcare setting.
About SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma (schott-pharma.com) designs containment solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 30,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,800 people from over 65 nations works at SCHOTT Pharma to contribute to global health. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 986 million in the fiscal year 2025. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment.
|
lea.kaiser[.]schott.com 
